The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [70]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Survival Analysis Techniques for Censored and Truncated Data
Rao, M. B., Klein, J. P., & Moeschberger, M. L. (1998) · Technometrics · doi:10.2307/1270658 · Cited by 3,617
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,010
Hanna, G. J., Woo, S.-B., Li, Y. Y., Barletta, J., Hammerman, P. S., & Lorch, J. (2017) · International Journal of Oral & Maxillofacial Surgery · doi:10.1016/j.ijom.2017.09.006 · Cited by 52
Soulières, D., Licitra, L. F., Mesı́a, R., Remenár, É., Li, S.-H., Karpenko, A., Chol, M., Wang, Y. A., Solovieff, N., Bourdeau, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2644 · Cited by 54
Self-citationUpdate on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Abu‐Sbeih, H., Tang, T., Ali, F. S., Johnson, D. H., Qiao, W., Diab, A. K., & Wang, Y. (2018) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_12_18 · Cited by 53
Leshem, Y., & Pastan, I. H. (2019) · Toxins · doi:10.3390/toxins11010020 · Cited by 52
Eder, T., Hess, A. K., Konschak, R., Stromberger, C., Jöhrens, K., Fleischer, V., Hummel, M., Balermpas, P., von der Grün, J., Linge, A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.015 · Cited by 56
Elbers, J. B. W., Al‐Mamgani, A., Tesseslaar, M. E. T., van den Brekel, M. W. M., Lange, C. A. H., van der Wal, J. E., Verheij, M., Zuur, C. L., & de Boer, J. P. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.08.007 · Cited by 51
The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality
Ferrari, D., Ghi, M. G., Franzese, C., Codecà, C., Gau, M., & Fayette, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00007 · Cited by 53
Self-citationLau, A., Yang, W., Li, K. Y., & Su, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102984 · Cited by 53
Personalized cancer vaccination in head and neck cancer
Shibata, H., Zhou, L., Xu, N., Egloff, A. M., & Uppaluri, R. (2020) · Cancer Science · doi:10.1111/cas.14784 · Cited by 54
Okada, M., Kato, K., Cho, B. C., Takahashi, M., Lin, C.-Y., Chin, K., Kadowaki, S., Ahn, M., Hamamoto, Y., Doki, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0985 · Cited by 53
Tahara, M., Muro, K., Hasegawa, Y., Chung, H., Lin, C.-C., Keam, B., Takahashi, K., Cheng, J. D., & Bang, Y. (2018) · Cancer Science · doi:10.1111/cas.13480 · Cited by 50
Self-citationFu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
Aggarwal, C., Saba, N. F., Algazi, A. P., Sukari, A. W., Seiwert, T. Y., Haigentz, M., Porosnicu, M., Bonomi, M. R., Boyer, J., Esser, M. T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1987 · Cited by 53
Self-citationCTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma
Wang, S., Wu, Z., Zhu, S., Wan, S., Zhang, M.-J., Zhang, B., Yang, Q., Xiao, Y., Li, H., Mao, L., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.023 · Cited by 52
Gavrielatou, N., Fortis, E., Spathis, A., Anastasiou, Μ., Economopoulou, P., Foukas, G. R. P., Lelegiannis, I. M., Rusakiewicz, S., Vathiotis, I. A., Aung, T. N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.011 · Cited by 53
Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control
Weiss, S. A., Huang, A. Y., Fung, M. E., Martínez, D., Chen, C.-Y., LaSalle, T. J., Miller, B. C., Scharer, C. D., Hegde, M., Nguyen, T. H., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01961-3 · Cited by 56
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 52
Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆
Ward, M. C., Shah, C., Adelstein, D. J., Geiger, J. L., Miller, J. A., Koyfman, S. A., & Singer, M. E. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.09.017 · Cited by 52
Programmed death ligand‐1 expression as immunotherapeutic target in sinonasal cancer
Riobello, C., Vivanco, B., Reda, S., López‐Hernández, A., García–Inclán, C., Potes‐Ares, S., Cabal, V. N., López, F., Llorente, J. L., & Hermsen, M. A. J. A. (2018) · Head & Neck · doi:10.1002/hed.25067 · Cited by 55
Varki, V., Ioffe, O. B., Bentzen, S. M., Heath, J., Cellini, A., Feliciano, J. L., & Zandberg, D. P. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2138-8 · Cited by 52
Haque, S., Karivedu, V., Riaz, M. K., Choi, D., Roof, L., Hassan, S., Zhu, Z., Jandarov, R., Takiar, V., Tang, A. L., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.11.010 · Cited by 47
Xu, M., Nie, Y., Yang, Y., Lu, Y.-T., & Su, Q. (2019) · The Neurologist · doi:10.1097/nrl.0000000000000230 · Cited by 56
PD-L1/PD-1 axis as a potent therapeutic target in breast cancer
Bastaki, S., Irandoust, M., Ahmadi, A., Hojjat‐Farsangi, M., Ambrose, P., Hallaj, S., Edalati, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117437 · Cited by 51
Tinhofer, I., Braunholz, D., & Klinghammer, K. F. (2020) · Cancers of the Head & Neck · doi:10.1186/s41199-020-00056-4 · Cited by 55
Lonardi, S., Prete, A. A., Morano, F., Messina, M., Formica, V., Corsi, D. C., Orciuolo, C., Frassineti, G. L., Zampino, M. G., Casagrande, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002996 · Cited by 56
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Ran, X., & Yang, K. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s140687 · Cited by 51
Li, Y., Zhang, Y., Cao, G., Zheng, X., Sun, C., Wei, H., Tian, Z., Xiao, W., Sun, R., & Sun, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01112-3 · Cited by 51
Bauman, J. E., Cohen, E. E. W., Ferris, R. L., Adelstein, D. J., Brizel, D. M., Ridge, J. A., O’Sullivan, B., Burtness, B. A., Butterfield, L. H., Carson, W. E., et al. (2016) · Cancer · doi:10.1002/cncr.30449 · Cited by 51
Self-citationRadiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Colen, R. R., Rolfo, C. D., Ak, M., Ayoub, M., Ahmed, S., Elshafeey, N. A., Mamindla, P., Zinn, P. O., Ng, C. S., Vikram, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001752 · Cited by 54
Haist, C., Schulte, E., Bartels, N., Bister, A., Poschinski, Z., Ibach, T. C., Geipel, K., Wiek, C., Wagenmann, M., Monzel, C., et al. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105259 · Cited by 51
Li, X., Fang, Q., Du, W., Zhang, X., Dai, L., & Qiao, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08373-8 · Cited by 53
He, F., Chen, Z., Deng, W., Zhan, T., Huang, X., Zheng, Y., & Yang, H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107789 · Cited by 51
Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
Fernandez, A., O’Leary, C. G., O'Byrne, K. J., Burgess, J. T., Richard, D. J., & Suraweera, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.685440 · Cited by 51
Gong, W., Donnelly, C. R., Heath, B. R., Bellile, E. L., Donnelly, L. A., Taner, H. F., Broses, L. J., Brenner, J. C., Chinn, S. B., Ji, R., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1997385 · Cited by 51
PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
Lima, Á., de Sousa, H. M. L., Medeiros, R., Nobre, A., & Machado, M. (2022) · Discover Oncology · doi:10.1007/s12672-022-00479-0 · Cited by 51
Davar, D., Zappasodi, R., Wang, H., Naik, G. S., Sato, T., Bauer, T. M., Bajor, D. L., Rixe, O., Newman, W., Qi, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0339 · Cited by 51
Sano, Y., Kogashiwa, Y., Araki, R., Enoki, Y., Ikeda, T., Yoda, T., Nakahira, M., & Sugasawa, M. (2018) · Otolaryngology · doi:10.1177/0194599817745284 · Cited by 51
First-line treatment of ovarian cancer: questions and controversies to address
Ledermann, J. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918768232 · Cited by 51
Immunological and classical subtypes of oral premalignant lesions
Foy, J.-P., Bertolus, C., Ortiz-Cuàran, S., Albaret, M., Williams, W. N., Lang, W., Destandau, S., Souza, G. D., Sohier, E., Kielbassa, J., et al. (2018) · Oncoimmunology · doi:10.1080/2162402x.2018.1496880 · Cited by 41
Batenchuk, C., Albitar, M. X., Zerba, K. E., Sudarsanam, S., Chizhevsky, V., Jin, C., & Burns, V. A. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205362 · Cited by 51
Bonomo, P., Greto, D., Desideri, I., Loi, M., Cataldo, V. D., Orlandi, E. M., Iacovelli, N. A., Becherini, C., Visani, L., Salvestrini, V., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.04.006 · Cited by 51
Beckham, T. H., Leeman, J. E., Xie, P., Li, X., Goldman, D. A., Zhang, Z., Sherman, E. J., McBride, S. M., Riaz, N., Lee, N. Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0601-8 · Cited by 51
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Cristina, V., Gómez, R. G. H., Szturz, P., Espeli, V. G., & Siano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215399 · Cited by 52
Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat
Perri, F., Longo, F., Caponigro, F., Sandomenico, F., Guida, A., Scarpati, G. D. V., Ottaiano, A., Muto, P., & Ionna, F. (2020) · Cancers · doi:10.3390/cancers12040975 · Cited by 51
Lu, H., Dai, W., Guo, J., Wang, D.-K., Wen, S., Yang, L., Lin, D.-J., Xie, W., Wen, L., Fang, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573920 · Cited by 46
Zhang, Y., Lin, A., Li, Y., Ding, W., Meng, H., Luo, P., & Zhang, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608969 · Cited by 51
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Zhou, L., Zeng, Z., Egloff, A. M., Zhang, F., Guo, F., Campbell, K. M., Du, P. P., Fu, J., Zolkind, P., Ma, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004034 · Cited by 49
Self-citationMukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., & Chappell, R. J. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2666 · Cited by 50
Salvato, I., & Marchini, A. (2024) · Cancers · doi:10.3390/cancers16071276 · Cited by 51
Lee, V., Kwong, D., Leung, T., Lam, K., Tong, C. C., & Lee, A. W. M. (2017) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2017.03.030 · Cited by 51
Kansy, B., Shayan, G., Jie, H.-B., Gibson, S. P., Lei, Y. L., Brandau, S., Lang, S., Schmitt, N. C., Ding, F., Lin, Y., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1494112 · Cited by 51
Self-citationPai, S. I., Faivre, S. J., Licitra, L. F., Machiels, J.-P., Vermorken, J. B., Bruzzi, P., Gruenwald, V., Giglio, R., Leemans, C. R., Seiwert, T. Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0578-0 · Cited by 50
Self-citationSakakida, T., Ishikawa, T., Uchino, J., Chihara, Y., Komori, S., Asai, J., Narukawa, T., Arai, A., Kobayashi, T., Tsunezuka, H., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10466 · Cited by 50
Xu, B., Jungbluth, A. A., Frosina, D., Alzumaili, B., Aleynick, N., Slodkowska, E. A., Higgins, K. M., Ho, A. L., Morris, L. G. T., Ghossein, R. A., et al. (2019) · Histopathology · doi:10.1111/his.13944 · Cited by 51
Okamoto, I., Sato, H., Kondo, T., Koyama, N., Fushimi, C., Okada, T., Miura, K., Matsuki, T., Yamashita, T., Omura, G., et al. (2019) · Acta Oto-Laryngologica · doi:10.1080/00016489.2019.1648867 · Cited by 50
Juliá, E. P., Mandó, P., Rizzo, M., Cueto, G. R., Tsou, F., Luca, R., Pupareli, C. S., Bravo, A., Astorino, W., Mordoh, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02391-z · Cited by 50
Sasaki, A., Kawazoe, A., Eto, T., Okunaka, M., Mishima, S., Sawada, K., Nakamura, Y., Kotani, D., Kuboki, Y., Taniguchi, H., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000775 · Cited by 50
Morimoto, K., Uchino, J., Yokoi, T., Kijima, T., Gotô, Y., Nakao, A., Hibino, M., Takeda, T., Yamaguchi, H., Takumi, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950411 · Cited by 49
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition
Yuan, J. D., Khilnani, A. D., Brody, J., Andtbacka, R. H. I., Hu‐Lieskovan, S., Luke, J. J., Diab, A. K., Marabelle, A., Snyder, A., Cao, Z. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.004 · Cited by 50
Ghate, K., Amir, E., Kuksis, M., Barajas, D. H., Rodríguez‐Romo, L., Booth, C. M., & Vera-Badillo, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.002 · Cited by 49
Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression
Wang, H., Gao, J., Zhang, R., Li, M., Peng, Z., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106478 · Cited by 49
Clubb, J. H. A., Kudling, T. V., Heiniö, C., Basnet, S., Pakola, S. A., Cervera-Carrascón, V., Santos, J. M., Quixabeira, D. C. A., Havunen, R., Sorsa, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.794251 · Cited by 51
Ge, J., Meng, Y., Guo, J., Chen, P., Wang, J., Shi, L., Wang, D., Qu, H., Wu, P., Fan, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52981-4 · Cited by 49
Advances and challenges in immunotherapy in head and neck cancer
Aboaid, H., Khalid, T., Hussain, A., Myat, Y. M., Nanda, R. K., Srinivasmurthy, R., Nguyen, K., Jones, D. T., Bigcas, J., & Thein, K. Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1596583 · Cited by 49
Martini, D. J., Lalani, A. A., Bossé, D., Steinharter, J. A., Harshman, L. C., Hodi, F. S., Ott, P. A., & Choueiri, T. K. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0273-y · Cited by 49
Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response
Rosenberg, A. J., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.13 · Cited by 48
HPV – Das andere Kopf-Hals-Karzinom
Wittekindt, C., Wagner, S., Sharma, S. J., Würdemann, N., Knuth, J., Reder, H., & Klußmann, J. P. (2018) · Laryngo-Rhino-Otologie · doi:10.1055/s-0043-121596 · Cited by 58
Pauw, I. D., Lardon, F., den Bossche, J. V., Baysal, H., Fransén, E., Deschoolmeester, V., Pauwels, P., Peeters, M., Vermorken, J. B., & Wouters, A. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12197 · Cited by 51
Lin, W., Chen, M., Hong, L., Zhao, H., & Chen, Q. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00532 · Cited by 52
Deng, W., Li, Y., Ma, S., Mao, L., Yu, G., Bu, L., Kulkarni, A. B., Zhang, W., & Sun, Z. (2018) · International Journal of Cancer · doi:10.1002/ijc.31534 · Cited by 50
Reguera-Nuñez, E., Xu, P., Chow, A., Man, S., Hilberg, F., & Kerbel, R. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0999-5 · Cited by 51
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Y., & Li, G. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0674-4 · Cited by 49
Immunotherapy for head and neck cancer: where are we now and where are we going?
Bauml, J., Aggarwal, C., & Cohen, R. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.58 · Cited by 45
Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer
Wang, H., Wang, S., Huang, M.-C., Liang, X., Tang, Y.-J., & Tang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00498 · Cited by 55
Yoo, S. H., Keam, B., Ock, C.-Y., Kim, S., Han, B., Kim, J., Lee, K., Jeon, Y. K., Jung, K. C., Chung, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44206-2 · Cited by 49
The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC
Stafford, M. A., & Kaczmar, J. M. (2020) · Cancers of the Head & Neck · doi:10.1186/s41199-020-00052-8 · Cited by 48
Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index
Pollack, R. M., Ashash, A., Cahn, A., Rottenberg, Y., Stern, H., & Dresner–Pollak, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa458 · Cited by 49
Jiang, A., Ren, M., Liu, N., Gao, H., Wang, J.-J., Zheng, X., Fu, X., Liang, X., Ruan, Z., Tian, T., et al. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51064 · Cited by 50
Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., & Shen, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040520 · Cited by 50
Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma
Huang, H., Li, S., Tang, Q., & Zhu, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680955 · Cited by 49
Phase separation in Cancer: From the Impacts and Mechanisms to Treatment potentials
Qiu, P., Tan, S., Xia, L., Wu, N., Oyang, L., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75410 · Cited by 49
Feng, B., Shen, Y., Hostench, X. P., Bieg, M., Plath, M., Ishaque, N., Eils, R., Freier, K., Weichert, W., Zaoui, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3997 · Cited by 48
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2020) · Cancers · doi:10.3390/cancers12113377 · Cited by 48
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
Julian, R. A., Savani, M., & Bauman, J. E. (2021) · Cancers · doi:10.3390/cancers13235889 · Cited by 51
Cohen, E. E. W., Nabell, L., Wong, D. J., Day, T., Daniels, G. A., Milhem, M. M., Deva, S., Jameson, M. B., Guntinas-Lichius, O., Almubarak, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1411 · Cited by 48
Which test for crossing survival curves? A user’s guideline
Dormuth, I., Liu, T., Xu, J., Yu, M., Pauly, M., & Ditzhaus, M. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01520-0 · Cited by 48
Poulose, J. V., & Kainickal, C. T. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i5.388 · Cited by 48
Ahmed, K. M., Veeramachaneni, R., Deng, D., Putluri, N., Putluri, V., Cardenas, M., Wheeler, D. A., Decker, W. K., Frederick, A. I., Kazi, S. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004752 · Cited by 49
Fitzsimmons, T. S., Singh, N., Walker, T. D. J., Newton, C. L., Evans, D. G., Crosbie, E. J., & Ryan, N. A. J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1192762 · Cited by 48
Miyazaki, N. L., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2023) · Cancers · doi:10.3390/cancers15215117 · Cited by 49
Theodoraki, M., Lorenz, K., Lotfi, R., Fürst, D., Tsamadou, C., Jaekle, S., Mytilineos, J., Brunner, C., Theodorakis, J., Hoffmann, T., et al. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.05.015 · Cited by 46
Miles, B. A., Safran, H. P., & Monk, B. J. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0047-8 · Cited by 48
Guigay, J., Tahara, M., Licitra, L. F., Keilholz, U., Friesland, S., Witzler, P., & Mesı́a, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00668 · Cited by 48
Self-citationLow doses in immunotherapy: Are they effective?
Prabhash, K., Patil, V. M., Noronha, V., Joshi, A. D., Abhyankar, A. V., Menon, N. S., Banavali, S. D., & Gupta, S. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_29_19 · Cited by 48
Ninomiya, K., Oze, I., Kato, Y., Kubo, T., Ichihara, E., Rai, K., Ohashi, K., Kozuki, T., Tabata, M., Maeda, Y., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1695062 · Cited by 48
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 48
Ye, W., Gunti, S., Allen, C. T., Hong, Y., Clavijo, P. E., Waes, C. V., & Schmitt, N. C. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1710398 · Cited by 52
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1856-1867
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5564292
- OpenAlex
- W2529484692
- Cited by
- 5,101
- References
- 26
- Citations by year
- 2026: 358 · 2025: 461 · 2024: 500 · 2023: 490 · 2022: 574 · 2021: 687 · 2020: 617 · 2019: 543 · 2018: 486 · 2017: 358 · 2016: 17
- FWCI
- 452.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Ono Pharmaceutical
- National Cancer Institute (P50CA097190, R01CA206517)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- nivolumab, PD-1 inhibitors, immune checkpoint inhibitors, platinum-refractory disease, overall survival, progression-free survival, objective response rate, quality of life, treatment-related adverse events, cetuximab, docetaxel, methotrexate, single-agent chemotherapy, metastatic head and neck cancer, immunotherapy
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
